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Abstract
Bitter taste is sensed by bitter taste receptors (TAS2Rs) that belong to the G protein-coupled
receptor (GPCR) superfamily. In addition to bitter taste perception, TAS2Rs have been reported
recently to be expressed in many extraoral tissues and are now known to be involved in health
and disease. Despite important roles of TAS2Rs in biological functions and diseases, no crystal
structure is available to help understand the signal transduction mechanism or to help develop
selective ligands as new therapeutic targets. We report here the three-dimensional structure of
the fully activated TAS2R4 human bitter taste receptor predicted using the GEnSeMBLE
complete sampling method. This TAS2R4 structure is coupled to the gustducin G protein and
to each of several agonists. We find that the G protein couples to TAS2R4 by forming strong salt
bridges to each of the three intracellular loops, orienting the activated Gα5 helix of the Gα
subunit to interact extensively with the cytoplasmic region of the activated receptor.We find that
the TAS2Rs exhibit unique motifs distinct from typical Class A GPCRs, leading to a distinct
activation mechanism and a less stable inactive state. This fully activated bitter taste receptor
complex structure provides insight into the signal transduction mechanism and into ligand
binding to TAS2Rs.
Introduction
Bitter taste perception is generally assumed to protect an organism against potentially toxic
substances that are sensed by bitter taste receptors (TAS2Rs). TAS2Rs belong to the G protein-
coupled receptors (GPCRs) superfamily with 25 expressed in humans. The TAS2Rs interact with a
large and diverse group of compounds. Surprisingly, TAS2Rs are expressed not only in the oral
cavity but also in many extraoral tissues, including gastrointestine (Wu et al., 2002), nasal
epithelium (Finger et al., 2003), airway (Deshpande et al., 2010), skin (Shaw et al., 2018), heart
(Foster et al., 2014) and brain (Singh et al., 2011a). It has been reported that TAS2Rs expressed in
extraoral tissues are deeply involved in health and disease by contributing to physiological
functions, such as sensing potentially harmful molecules and regulating the metabolic/immune
system (Lu et al., 2017). To date, a number of studies have reported about TAS2Rs-associated
disorders and diseases including food intake (Andreozzi et al., 2015), insulin homeostasis (Dotson
et al., 2008), cardiovascular disease (Shiffman et al., 2008) and cancer (Martin et al., 2019).
Despite crucial roles in physiological functions and related diseases, investigations on TAS2Rs
have been hampered by the lack of structural information. Neither X-ray crystal nor cryo-
electron microscopy (EM) structures are available for TAS2Rs. Thus the only structural infor-
mation is from several predicted structures based mostly on homology modelling using Class A
GPCRs (Singh et al., 2011b; Di Pizio & Niv, 2015; Pydi et al., 2015; Pándy-Szekeres et al., 2018).
Such homology models for GPCRs are problematic because the seven transmembrane domains
(TMD) form nearly parallel α-helices so that their axial orientation is highly sequence dependent.
Moreover, although TAS2Rs are generally classified as Class A GPCRs, the sequence similarity of
TAS2Rs with other class AGPCRs is much less than 30% (Di Pizio et al., 2016)making homology
modelling even less reliable. To ameliorate this problem we developed a systematic approach to
take a GPCR with a known structure as a template to fix the initial tilts for the seven TMDs and
then sampling first all coupled axial rotations (BiHelix step, 35 million combinations) (Abrol
et al., 2012) and then various combinations of tilts and rotations (SuperBiHelix, 13 trillion
combinations) (Bray et al., 2014) combined with side chain optimization (SCREAM) to finally
select the lowest 25 conformation likely to play a role in ligand binding. This methodology,
referred to as the GPCR ensemble of structures in membrane bilayer environment
(GEnSeMBLE), has been successful for predicting other GPCRs, including Class A [CCR5
(Berro et al., 2013; Abrol et al., 2014), AA3 (Goddard et al., 2010), DP prostaglandin (Shankar
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2012)] and Class C [TAS1R2/1R3 sweet heterodimer (Kim et al.,
2017)], but this is the first application of this methodology to
TAS2Rs [an earlier application of some of these tools was used to
predict the structure of TAS2R38 (Tan et al., 2012)].
Having the structure for the GPCR is just the first step. To
describe the signal transduction we must consider how binding of
agonist and G protein (GP) to the GPCR leads to activation. We
find that binding an agonist to the GPCR-GP complex results in a
conformational change of the GPCR that is transmitted to the
bound GP, leading to opening the tight GP-GDP complex to form
the activated state with an open Gα subunit. In our recent report for
κ opioid receptor (κOR), we found that the Gi protein (GiP) makes
strong anchors to all three intracellular loops (ICLs) of the κOR,
stabilizing the active conformation of GPCR (Mafi et al., 2020a,
2020b). This indicates that both ligand and GP interacting with the
GPCR lead to structural changes that stabilize the final activated
state. Therefore, to understand the factors responsible for attaining
the fully activated GPCR-agonist-GP complex structure, we need to
understand the role of these three components. This should help
develop a structural basis for developing new more selective and
active agonists or antagonists.
In this study, we describe the prediction of the three-
dimensional (3D) structure of the fully activated TAS2R4 human
bitter taste receptor with several agonists using the GEnSeMBLE
(Abrol et al., 2012; Bray et al., 2014) and DarwinDock (Griffith,
2017) complete sampling methods. We find that the agonist bind-
ing modifies the hydrogen-bond (HB) network in the binding
pocket, which triggers a shift in the conformation of Y6.48, which
probably acts as a transmission switch similar to that observed in
typical Class A GPCRs. Moreover, we find that the GP, gustducin
heterotrimeric protein (responsible for the bitter and basic taste;
hereafter referred to as Ggust), binds to the TAS2R4 by forming salt
bridge (SB) anchors to each of the three ICLs of TAS2R4, orienting
the Gα5 helix to make extensive interactions with residues in the
cytoplasmic region of TAS2R4. We also find several unique motifs
conserved only across TAS2Rs that result in an activation mecha-
nism distinct from that of typical Class A GPCRs. The structure of
this fully activated TAS2R4-agonist-Ggust complex provides infor-
mation that should be useful in understanding universal and
diverse features across other TAS2Rs and for other subfamilies of
GPCRs.
Results and discussion
Structural prediction for TAS2R4
Since no crystal structure is available for TAS2Rs, we predicted the
7-helix TMD of TAS2R4 using the GEnSeMBLE complete sam-
pling technique. This method has successfully predicted 3D struc-
tures of many GPCRs (Goddard et al., 2010; Abrol et al., 2012;
Kirkpatrick et al., 2012; Tan et al., 2012; Ahn et al., 2013; Berro et al.,
2013; Scott et al., 2013; Abrol et al., 2014; Bray et al., 2014; Kim
et al., 2017; Shankar et al., 2018). The first step in GEnSeMBLE is to
select a template from known structures to specify the initial tilts of
the seven TMDs. Despite its low sequence similarity, most analyses
support the classification of TAS2Rs with Class A GPCRs (Di Pizio
and Niv, 2015; Di Pizio et al., 2016). Therefore, based on the
sequence alignment for Class A GPCRs for which active structures
are available, we selected four templates with highest homology to
TAS2R4 for the GEnSeMBLE predictions (Table S1)); serotonin 2C
(5-HT2C), angiotensin 2 (AT2), cannabinoid 1 (CB1) and rhodop-
sin. For each template we mapped the residues to TAS2R4 and
examined coupled 30° rotations about the tilt axis of all seven TMDs.
This BiHelix step examines 12**7=35 million combinations from
which we select 2,000 that we build into 7-helix bundles while
reoptimizing side chain conformations. From these 2,000 conforma-
tions we examined the 10 lowest energy shown in Table S2. We
then selected two structures based on energy and diversity for the
SuperBiHelix step that considers changing the tilt polar angle (θ) by
10°, the tilt azimuthal angle (ϕ) by15°,30° and each axial angle
(χ) by 15°, 30° for a total of (3 5 5)**7=13 trillion confor-
mations. For each of these two cases, we select the 2,000 from
SuperBiHelix predicted to have the lowest energy that we build into
7-helix bundles while reoptimizing side chain conformations by
SCREAM. From this 2 2,000 we selected the best 25 by energy
and diversity, as shown in Table S3, for docking each agonist. From
these 25 we finally selected the energetically most favourable struc-
ture obtained from the 5-HT2C template for further study (Fig. S1).
Ligand binding
Ligand binding site
Over 30 compounds are known to activate TAS2R4 (Wiener et al.,
2012).Of these, 10 ligands showbinding constants of 100μMeffective
concentration or stronger. Many of these ligands are not-specific to
TAS2R4 (Table S4). Rubusoside (Rubu), a steviol glycoside isolated
from the Chinese sweet tea plant Rubus suavissimus, is known to
bind to TAS2R4 with 50μM effective concentration (and to
TAS2R14 with 400μM effective concentration). Although steviol
glycosides are generally known as nonnutritive sweeteners, they
elicit a lingering bitter aftertaste that is mediated by TAS2R4 and
TAS2R14 (Hellfritsch et al., 2012). Thus, we focus on Rubu as an
agonist of TAS2R4, which we compare to quinine, a well-known
bitter compound that binds to several bitter receptors, including
TAS2R4.
We used DarwinDock to predict the binding poses of Rubu and
quinine to the most favourable 7-TMD conformation of TAS2R4
predicted by GEnSeMBLE (Fig. S2). DarwinDock considers
~50,000 poses of the ligand in the protein binding site and selects
the top 100 by energy. In this process the six hydrophobic residues
(I, L, V, F, Y andW) are replaced byAla to allow space for sampling,
but after selecting the top 100 poses by energy, we use SCREAM to
add back these hydrophobic residues independently to each pose to
provide each ligand pose a unique environment (Li et al., 2015).
Then we select the lowest energy poses for further analysis.
We find that Rubu forms HBs to one residue in TM3
(D923.36) and two in TM7 (K2627.35 and S2637.36) (the superscript
is Ballesteros–Weinstein GPCR numbering (Ballesteros andWein-
stein, 1995)). Charged (or polar) residues in TM3 of the binding
pocket often play a crucial role in the ligand recognition and
binding for Class AGPCRs, such as D3.32 for β2 adrenergic receptor
(β2AR) and all opioid receptors. Similarly, we find that D923.36
plays an important role in Rubu binding to TAS2R4, as discussed in
detail below. This D923.36 in TAS2R4 is unique among TAS2Rs,
wheremost TAS2Rs have asparagine at this position (Fig. S3). Thus
D923.36 may play an important role in selectivity for TAS2R4.
Quinine is known to have a protonated nitrogen at physiological
conditions (Thompson et al., 2007), and our docking studies find
that it makes a SB with D923.36. However, quinine is known to bind
to nine other TAS2Rs that do not have a negatively charged residue
at position 3.36, yet they lead to similar or even higher binding
affinity (Wiener et al., 2012). Thus we expect that formation of this
SB is not likely to be essential for binding of quinine and may not
induce a higher binding affinity. In addition to this interaction with
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D923.36, quinine forms HBs to residues in TM5 (S1845.46) and TM6
(Y2426.51). These interactions of Rubu and quinine with TAS2R4
obtained fromdocking evolved duringMD simulations after insert-
ing in lipid bilayer and water box, as discussed below.
Steviol glycosides have a steviol as a core structure, containing a
carboxyl hydrogen (R1 side) and a hydroxyl hydrogen (R2 side) at
each end, with R1 and R2 replaced by various sugars (glucose or
rhamnose) as shown in Fig. 1a. Rubu is the smallest among steviol
glycosides, with just a glucose ring at each end of the core structure
(Table S5). During the MD simulations with full lipid bilayer and
solvent for 480 ns, Rubu made interactions with residues in TM3,
TM4, TM5, TM6 and extracellular loop 2 (ELC2) (Fig. 1c, S4A and
Table S6). Due to the hydrophobic core and the hydrophilic sugar
rings of Rubu, residues in the middle of the binding pocket and
close to the steviol core contribute to the binding mainly through
hydrophobic interactions, whereas those close to the sugar rings are
involved in HBs and polar interactions. The MD simulations were
carried out with the GP bound (TAS2R4-agonist-Ggust); interac-
tions between GPCR and Ggust are discussed in section ‘TAS2R4 in
complex with the full heterotrimeric gustducin G protein.
In comparison, quinine is relatively small, interacts with fewer
residues in TM3, TM5, and TM6 (Fig. 1b,d, S5A and Table S6). Van
der Waals or hydrophobic interactions dominate, except for the SB
interaction of the quinine tertiary nitrogen with D923.36.
In addition to Rubu, other bulkier steviol glycosides can also
activate TAS2R4 (Hellfritsch et al., 2012), although experimental
result shows that those are not as bitter as Rubu (Table S5). For
example, RebaudiosideM (RebM) has six sugar rings (three on each
side of the core) and exhibits moderate bitterness. To investigate
how such bulkier ligands bind to TAS2R4 and their activity (bit-
terness), we predicted an initial binding pose of RebM by matching
to that of Rubu. This is because its large size complicates getting
accurate results directly from docking. Then we performed MD
simulation to equilibrate RebM in the binding site. We find that
RebM makes more interactions with residues in TM2, TM7 and
ECL1, compared to Rubu (Figs S6A, S6B and Table S6). It has been
reported that TM1, TM2 and TM7 are more involved in binding of
antagonists (Di Pizio et al., 2016), which may be a reason for RebM
being much less bitter than Rubu. Although the six sugar rings of
RebM lead to a number of degrees of freedom with many possible
conformations of the sugar rings that might lead to a different
binding mode, the TAS2R4-RebM-Ggust complex seems converged
after 480 ns of MD simulations (Fig. S6C).
A derivative of RebM, hydRebM, exhibits much less bitterness,
despite a very similar structure (Table S5). The only difference with
RebM is that an alkene group in the core structure is substituted with
hydroxyl and methyl groups. In comparison, isoRebM, in which the
double bond of the alkene is shifted to the next carbon in the ring,
shows bitterness similar to that of RebM (Table S5). These dramatic
differences in activation for similar structures indicate that the
hydroxyl group in hydRebM must play a role in suppressing activa-
tion. Indeed as described below our MD simulations show that this
hydroxyl group makes an internal HB with one of R2 sugars, which
may hinder the proper positioning of the ligand for binding and
activation (Figs S7 and S8B). This hydroxyl group also makes an
HB with Y2506.59, which may lead to a change in the hydRebM
binding pose or it may act to restrict the structural change of TM6
for activation, but this interactionwas not retained during the dynam-
ics (Fig. S8C). For theRubu andRebMsystems,we found thatY2506.59
contributes to the binding, but mainly through hydrophobic interac-
tions (Table S6). To fully understand the difference in bitterness across
steviol glycosides, it may be necessary to investigate the transition in
which the GP induces the inactive state to form the fully active state.
The transmission switch of Y2396.48
Among the residues in the binding pocket, D923.36 likely plays a
particularly crucial role in ligand binding. It forms two stable HBs
withRubu and a SBwith quinine, contributing to almost¼ and½of
the total binding, respectively (Fig. 1, S4C and S5C and Table S6).
Not only does D923.36 provide a large energy stabilization via polar
interactions, but it contributes to transferring the signal for activa-
tion by changing the HB network (Fig. 2). Thus in the apo protein
structure from GEnSeMBLE, we find that D923.36 makes an HB
interaction with Y2396.48. But the presence of agonist causes the
side chain of Y2396.48 to break this interactionwithD923.36 so that it
rotates anti-clockwise. Indeed, it is well-known that the highly
conservedW6.48 in Class A GPCRs plays a crucial role in activation,
where it is known as a ‘transmission switch’ (Zhou et al., 2019).
Although Y2396.48 is not as highly conserved in TAS2Rs as is W6.48
in typical Class A GPCRs, this significant movement of Y2396.48
upon ligand binding suggests that this conformational change may
contribute to the rotation and structural change in TM6, which is
one of most significant changes between inactive and active states
observed in Class A GPCRs.
To validate this hypothesis, we prepared two structural models
without an agonist. The first model (model 1) is the one constructed
Fig. 1.Chemical structures of (a) the steviol glycosides and (b) quinine, where sugar (glucose or rhamnose) is attached at R1 and R2 in (a). Binding sites for (c) Rubu and (d) quinine to
TAS2R4. Rubu has HBs to residues in TM3 (F883.32, M893.33, D923.36, S933.37), TM4 (Y1474.62), TM5 (L1775.39, L1815.43), TM6 (Y2506.59) and ELC2 (E158, T162, N164). Quinine has a SB to
D923.36 and HBs to residues in TM3 (F883.32, M893.33), TM5 (L1815.43, Q1885.50) and TM6 (Y2426.51).
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by GEnSeMBLE (Fig. S1), where it was equilibrated with neither
agonist nor Ggust, although this model was constructed using an
activated GPCR as a template. The second model (model 2) is the
pre-activated structure, which contains no agonist but is coupled to
the inactiveGgust coupled toGDP. This ismotivated by our discovery
that GPs form anchors that induce the conformational change of the
receptor (Mafi et al., 2020a) discussed in the following section. This
led to our G protein-first hypothesis, in which GP binds first to the
receptor to initiate activation followed by agonist binding to com-
plete activation. Both models find that Y2396.48 maintains a stable
direct or water-mediated HB with D923.36 for 100ns of MD simu-
lation (Fig. S9A). A further metadynamics simulations (metaMD)
based free energy analysis shows an energyminimum corresponding
to a water-mediated HB between D923.36 and Y2396.48 (Fig. S9B).
Thus, Y2396.48 and D923.36 play crucial roles in the activation pro-
cess, just as does W6.48 for typical Class A GPCRs.
We attribute the decreased bitterness of RebM and hydRebM
relative to Rubu to the interaction of these ligands with Y2396.48.
Compared to Rubu, both RebM and hydRebM have two additional
sugar rings attached to the first sugar ring at the R1 side, and one
of these sugars can reach Y2396.48 to make an HB (Fig. S10). This
additional interaction may hinder the conformational change of
Y2396.48 needed for activation, resulting in suppressing activation.
A similar interaction may also account for the lower bitterness
observed in other bulky steviol glycosides (Table S5).
TAS2R4 complexed with the full heterotrimeric
gustducin G protein
Although structures for many GPCRs with ligand binding sites
have been predicted successfully using GEnSeMBLE and Darwin-
Dock, it remains a challenge to predict a fully activated structure
with decisive information for understanding the signal transduc-
tion mechanism and for developing new therapeutics. This is
because the activation process requires binding of both agonist
and the cognate GP. Both components are usually essential for
activating GPCRs to induce subsequent signal transduction. In our
recent MD and metaMD studies of κOR and μOR, we discovered
that these GPCRs binds strongly to its cognate GP via SB and HB
interactions at all three ICLs (Mafi et al., 2020a). These interactions
were not identified in the cryo-EM structures because of the low
resolution and disorder. To obtain this fully activated structure for
TAS2R4, we used the lessons from κOR and μOR to predict the
complex structure. Here we used the gustducin heterotrimeric
protein, which is responsible for the bitter taste.
Indeed, we found essentially the same interactions for the
TAS2R4-Ggust complex as forGiPwith κORand μOR. Fig. 3a shows
the equilibrated TAS2R4-Rubu-Ggust structure immersed in the
lipid bilayer. For the 480ns MD simulation, the root mean square
deviation (RMSD) of the TAS2R4 was within 3Å while that of the
whole protein complex was 4Å, showing the stability of the com-
plex structure (Fig. S4B).
• For anchor 1, we find that two positive residues in ICL1 form SBs
with two negative residues in the Gβ subunit, K37ICL1 –
D312Gβ and R40ICL1 – D333Gβ (Fig. 3b).
• For anchor 2, we find that R123 in ICL2 forms SBs with both
E25Gα and E28Gα of the Gα subunit (Fig. 3c).
• For anchor 3, we find that two lysine residues in ICL3 interact
with both the Gα5 helix and with the Ras-like domain of the Gα
subunit, K209(ICL3) – D341(D337)Gα and K212ICL3 – E318
(D316)Gα (Fig. 3d).
These residues involved in anchor formation were well posi-
tioned when we superimposed the mouse μOR-GiP structure with
TAS2R4-Ggust during themodel construction step (Fig. S11). A free
energy analysis using metaMD shows that these SBs should form
spontaneously with activation of Ggust as it approaches TAS2R4,
stabilizing the structural complex (Fig. S12). The three anchors
formed between TAS2R4 and Ggust were quite stable over ~0.5μs
MD simulation, although occasional fluctuations and switching of
SB pairs were observed (Fig. S4D–F).
We found similar interactions between TAS2R4 and Ggust for
the TAS2R4-quinine-Ggust complex structure (Fig. S5), and also for
the RebM and hydRebM systems (Figs S6 and S7). Therefore, we
conclude that this formation of anchors between Ggust and the ICLs
of the GPCR is likely a common feature across all TAS2Rs andClass
A GPCRs.
It is well known that activation of the GPCR-agonist-GP com-
plex involves coupling of the Gα5 helix of the Gα subunit with
residues deep in the GPCR (Onrust et al., 1997; Oldham et al., 2006;
Oldham & Hamm, 2008). Indeed for κOR and μOR we found that
Gα5 forms a network of HBs and SBs to the GPCR (Mafi et al.,
2020a). For these opioid receptors, a conserved arginine residue in
ICL2 (R170 for κOR and R179 for μOR respectively) plays an
important role in the interaction with Gα5, forming a SB with
D350Gα5. For TAS2R4, we find that the highly conserved
K1093.53 over all TAS2Rs plays the same role, forming a SB with
D350Gα5 (Fig. 3e).
For κOR and μOR the terminal carboxylate of Gα5 (F354) is also
important in proper positioning of the Gα5 helix, making a SB with
R6.32 in TM6 in the fully activated structure. For most TAS2Rs, we
expect an analogous interaction because most TAS2Rs have a
conserved positively charged residue in TM6 (6.32 or 6.36 position)
Fig. 2. (a) Top and (b) side views showing D923.36 – Y2396.48 interactions in the absence (cyan) and presence (tan) of the agonist, but the agonist is omitted for clarity.
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(Fig. S3). However TAS2R4 does not have a positively charged
residue at either the 6.32 or 6.36 position. Therefore, we expect
that F354Gα5 would make a SB with an alternative neighboring
positive residue in TAS2R4. Our predicted structure leads to two
candidates for this interaction, K2306.39 andK288H8, both of which
are well conserved (Figs 3e and S3). To test these possibilities we
first constructed a K2306.39 – F354Gα5 pair and carried out theMD
simulation, finding that it changed to the K2306.39 – K288H8 pair
(Fig. S4G). For the TAS2R4-quinine-Ggust complex structure,
F354Gα5 formed a SBwith both of these lysine residues, alternating
during theMD (Fig. S5G). For the RebM system F354Gα5 formed a
stable SB with K2306.39, whereas hydRebM shows an alternative
interaction of F354Gα5 with either K2306.39 or K288H8 (Figs S6H
and S7H). Although it is unclear whether this interaction should
depend on the ligand, we consider it likely that the terminal
carboxylate of Gα5 makes a SB with either or both of K2306.39
and K288H8 in TAS2R4.
We expect that the final position of theGα5 helix in the activated
structure may be achieved in stages. There are reports that there is
a stepwise sequential interactions of the Gα5 helix from its first
contact toward a deeper insertion that induces opening the
α-helical domain and GDP release (Du et al., 2019). Indeed, we
find that bringing the GDP bound Ggust towards the GPCR leads to
an initial SB contact of F354Gα5 with the highly conserved K1093.53
(Fig. S13). As the GP is activated the Ras-like domain and the
α-helical domain of the Gα subunit sandwiched around the GDP
open up so that GDP is exposed to exchange with GTP. Thus in the
activation mechanism, the Gα5 helix first interacts with the recep-
tor through the F354Gα5 – K1093.53 SB interaction, but then the
helix gradually inserts more deeply upon activation. During this
activation process, D350Gα5 makes a new SB with K1093.53 while
F354Gα5 forms a SB with K2306.39 (or K288H8) of TAS2R4. This
triggers the opening of the Gα and eventual GDP-GTP exchange
signaling. Interestingly, even for the structural model with the
inactive Ggust (tightly coupled to the GDP), residues involved in
the anchor formation were placed sufficiently close enough tomake
SBs (Fig. S13C–E). This suggests that the anchors form first, to help
to position the Gα5 helix for the insertion. In our previous study of
the κOR and μOR in which we discovered the formation of GPCR-
GiP anchors that induce conformational changes in the receptor, we
suggested the ‘G protein-first’ paradigm, in which GP binds first to
the receptor to initiate activation, followed by agonist binding to
further open the cytoplasmic region of the receptor to complete the
activation with GDP-GTP exchange (Mafi et al., 2020a). We sug-
gest that this applies to the TAS2Rs also.
Conserved motifs in TAS2Rs
The 1-2-7 interactions
Although TAS2Rs are generally considered to belong to Class A,
this classification of TAS2Rs is somewhat ambiguous due to the low
sequence similarity. Moreover, it is known that TAS2Rs have a
quite different pattern of conserved motifs compared to typical
Class A GPCRs (Di Pizio et al., 2016). For example typical Class A
GPCRs have highly conserved N1.50, D2.50 and N7.49 in the NPxxY
motif that can coordinate a sodium ion (or protonated H2O) and is
known as the sodium binding pocket (Liu et al., 2012). Based on
high-resolution X-ray structures, the sodium ion is coordinated
to the highly conserved D2.50 and S3.39 sites plus water molecules,
stabilizing the inactive conformation. This sodium ion binding
pocket is collapsed by the structural changes in the GPCR accom-
panying the activation process. For TAS2Rs, however, the aspartate
that plays a critical role in coordination of the sodium ion for Class
A is replaced with highly conserved arginine (Fig. S3). Thus, a
sodium ion is unlikely to bind at this site as observed in typical
Class A GPCRs. For TAS2Rs, mutagenesis studies show that the
S7.50A mutation induces hyperactivity (Pydi et al., 2012), leading
Pydi et al. to propose that S7.50 stabilizes the inactive state by
forming an HB with R2.50. However our MD simulations find that
in the active state, R552.50 forms an HB network with N241.50,
H2767.49 and S2777.50 (Fig. 4a). We found that this HB network
is stable and maintained for the full ~0.5μs MD simulation
(Fig. S14A–D). Moreover, our metaMD shows that this HB net-
work is energetically favourable (Fig. S14E). All residues involved in
this TM1–2-7 interaction are highly conserved, indicating that this
HB network plays an important role in the activation process for
TAS2Rs.
On the other hand, for the inactive structure constructed using
GEnSeMBLE based on the inactive 5-HT2C template and then
equilibrated (Table S7 and S8), we finds that R552.50 makes an
HB with S953.39, instead of N241.50, H2767.49, or S2777.50 (Fig. 4b).
Note that S3.39 is also a highly conserved residue in Class A GPCRs,
Fig. 3. (a) The structure of TAS2R4-Rubu-Ggust complex. Important polar interactions at three anchors: (b) anchor 1: ICL1 with Gβ, (c) anchor 2: ICL2 and GαN and (d) anchor 3: ICL3
and Gα. (e) Polar interactions between the Gα5 helix of the Gα subunit with TAS2R4.
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where it plays a role in binding sodium together with D2.50. In
contrast, S3.39 is less conserved in TAS2Rs, where it is oftenmutated
to threonine or asparagine (Fig. S3). Since the long side chain of
R552.50 canmake a direct HBwith S953.39 and there is no role for the
sodium ion as in Class A GPCRs, there has presumably been less
evolutionary pressure at this site in TAS2Rs, since it need only
to make an HB with R552.50. Our metaMD studies also indicate
that R552.50 prefers to interact with S953.39 rather than N241.50
(Fig. S15). These results indicate that R2.50 likely plays an important
role in activation, just as does D2.50 for typical Class A GPCRs, but
differently by stabilizing either the inactive or active state by
changing the HB network together with N1.50, S3.39, H7.49 and S7.50.
The DRY motif and E6.30
The D(E)3.49R3.50Y3.51 motif together with E(D)6.30 is another well
conserved motif in typical Class A GPCRs. The R3.50 – E(D)6.30 SB
interaction is considered to play a role in maintaining the inactive
state, where it is known as the ‘ionic lock’ (Zhou et al., 2019). For
TAS2Rs, however, neither the DRY motif nor E(D)6.30 is conserved,
and there is no alternative residue at a nearby position to form a SB
for the ionic lock. Some Class AGPCRs, such as the opioid receptors,
possess an HB that stabilizes the inactive state, instead of a SB,
although they still have the DRY motif in TM3.
For TAS2Rs, there are several candidates for this HB: Y1063.50 or
K1093.53 in TM3 and Q2216.30 in TM6 (Fig. S16A). Both residues
in TM3 are highly conserved, while the 6.30 position is also well
conservedwith a polar residue (usually serine) for TAS2Rs.However,
our metaMD studies on the inactive structure find that none of these
pairs are energetically favourable, suggesting that TAS2Rs may not
have a TM3-6 interaction stabilizing the inactive state (Figs S16B and
S16C). In fact, this possibility of a less stable inactive state or more
stable active state of TAS2Rs has been suggested from the signifi-
cantly different agonist-to-antagonist ratio of TAS2Rs compared to
other GPCRs (Di Pizio et al., 2016). Our results support the premise
that TAS2Rs have an intrinsically less stable inactive state. This may
be because of their roles in protecting animals from harmful com-
pounds, but further experimental studies are needed for validation.
Conclusion
We used advanced computational techniques to predict the 3D
structure of the fully activated TAS2R4 human bitter taste receptor
coupled to Ggust and to each of several agonists. We found that just
as for κORand μOR, theGgust forms stable SBswith all three ICLs of
TAS2R4 while the Gα5 helix makes extensive interactions with
residues in the cytoplasmic region of the GPCR. In the binding
pocket, D923.36 provides a large binding energy through polar
interactions with the agonist, while triggering rotation of Y2396.48
by changing the HB network. We find that the unique motifs
conserved in TAS2Rs play a role in the activation process but
differently compared to typical Class A GPCRs. We also find a less
stable inactive state, whichmay be an intrinsic property of TAS2Rs.
This structural information about the fully activated TAS2R4 bitter
taste receptor provides new insights that may be useful for under-
standing of variety of activation mechanisms for other TAS2Rs,
providing an insight into the diversity across the GPCR family.
These insights should provide guidance useful in developing new
therapeutic targets.
Methods
Modelling the human TAS2R4-ligand-G protein complex
The GEnSeMBLE technique (Abrol et al., 2012; Bray et al., 2014)
was used to predict the TMD of TAS2R4. The loops were con-
structedwithMODELLER (Fiser et al., 2000), using themouse μOR
structure (PDBID: 6DDF) as a template. DarwinDock (Griffith,
2017) was used to predict the binding site for Rubu and quinine to
the TAS2R4 TMD. Initial binding poses of RebM and hydRebM
were prepared by matching steviol cores to that of Rubu, followed
by 10 cycles of simulated annealing from 50K to 600K to optimize
the sugar positions. The nucleotide-free gustducin heterotrimeric
protein (Guanine nucleotide-binding protein Gt subunit alpha-3:
GNAT3, Guanine nucleotide-binding protein Gt subunit beta-1:
GNB1 and Guanine nucleotide-binding protein Gt subunit
gamma-13: GNG13) was constructed using our optimized GiP
complexed with μOR (Mafi et al., 2020a, 2020b) as a template to
perform homologymodelling using Prime (Schrödinger) (Jacobson
et al., 2004). The GiP was chosen because there is a reasonably high
similarity (>~ 63%) between these two heterotrimeric GP struc-
tures. Then, we included the myristoyl-Gly2 in the N-terminus of
the GαN helix. Similarly, the inactive Ggust bound GDP structure
was constructed using the crystal structure of heterotrimeric GiP
bound with GDP (PDBID: 1GOT) as a template for the homology
modelling. The initial structure of the TAS2R4-Rubu-Ggust com-
plex was modelled by superimposing the predicted human
TAS2R4-Rubu with the cryo-EM structure of mouse μOR-Gi
(PDBID: 6DDF).
System preparation and equilibration
The constructed protein was immersed into 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) lipid bilayer, using a pre-
equilibrated bilayer structure with 277 molecules (Dong et al.,
2016). The protein and lipid membrane were placed in a ~ 100
100 140Å3 box, with watermolecules and 100mM concentration
of ions (sodium and chloride). The final GPCR-Ggust system
Fig. 4. TM1–2-7 interactions (a) in the active state and (b) in the inactive state, respectively.
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contained 150,000 atoms. For the inactive structure the system
contained 160 POPCwith ~70,000 atoms total in a ~ 80 80 110
Å3 box. We used the Amber14 force field for proteins (Dickson
et al., 2014), Ambertools 16 for the lipid (Case et al., 2016) and the
generalized Amber force field for the ligands (Wang et al., 2004).
Water molecules were described using the TIP3P (Jorgensen et al.,
1983)model. Steepest-descent energyminimization was performed
first for the constructed system to relax the whole structure. Then,
we equilibrated with 5 ns MD simulation, while the positions of all
heavy atoms of proteins and ligands were restrained with a force
constant of ~2.4 kcal (molÅ2)1 for the first 1 ns, which was then
gradually reduced every 1 ns to 0.12 kcal (molÅ2)1. We continued
the equilibration with over 200 ns of NPT simulation (and over
100 ns for the inactive structure) without positional restraints to
relax the complex structure. During this equilibration step, parts of
the helices of TAS2R4, GαN and Gα5 of the Gα subunit, and
residues involved in important interactions were often constrained
with a force constant of ~1.2 kcal (molÅ2)1 to retain their sec-
ondary structures and interactions as the system was relaxed. For
free energy analyses, we applied the well-tempered metaMD
(Barducci et al., 2008) implemented in PLUMED (Tribello et al.,
2014). All simulations were carried out with a 2 fs time step at 310K
and 1 bar using the GROMACS (Abraham et al., 2015) MD soft-
ware with PLUMED. After the equilibration we carried out 480 ns
of MD on Anton2 (Shaw et al., 2014). VMD (Humphrey et al.,
1996) and Chimera (Pettersen et al., 2004) programs were partially
used for analysis and visualization.
Human bitterness scores
Pure (~98%) Stevia bitter glycosides were obtained from suppliers
(Chromadex Standards, Inc. Los Angeles, CA) or isolated from
Stevia leaf according to the procedures of Hellfritsch et al., (2012).
Samples were made by dissolving standards in pure sensory-grade
water at least 24 h before the test to various levels. Pyschophysical
measurements of bitterness intensity were performed as described
by Hellfritsch et al. (2012). The 300 ppm level was considered
typical for consumption in products such as beverages.
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